This is a rare condition that affects the eyes, brain, and skin. It causes inflammation in the eyes (uveitis and iritis), which can lead to glaucoma. It can also cause hair loss (alopecia), skin changes (vitiligo), and hearing problems. The brain may show signs of inflammation (meningitis), but it's not caused by infection. It's sometimes called VKH syndrome.
Every report comes from a Lived member, sent anonymously.
Have you tried Prednisone for Vogt-Koyanagi-Harada Syndrome?
Vogt-Koyanagi-Harada (VKH) syndrome is a rare autoimmune disease in which the immune system attacks melanocytes, the cells that make pigment. Because these cells are found in the eyes, the inner ear, the lining around the brain and the skin and hair, VKH can affect all of those places, although not always at once. Its central feature is uveitis: inflammation inside both eyes, especially in the choroid, the blood-vessel-rich layer beneath the retina. Fluid can collect under the retina and blur vision, sometimes severely. Many people first have a few days of flu-like symptoms such as headache, fever, nausea, a stiff neck or eye pain, and some notice ringing in the ears, hearing loss or dizziness. Weeks to months later, patches of skin may lose color (vitiligo), and hair, eyebrows or eyelashes may turn white or fall out. VKH matters because the eye inflammation can cause lasting vision loss if it is not treated quickly and thoroughly.
The cause of VKH is not known. It is understood as an autoimmune reaction, driven by immune cells called T cells, against proteins found in pigment cells. What sets that reaction off in a particular person is unclear; a viral infection or skin injury has been reported before some cases, but no trigger has been proven. VKH is more common in people with more skin pigment, including people of Hispanic, Asian, Native American and Middle Eastern descent, and it is less common in people of European or sub-Saharan African descent. In the United States it accounts for roughly 1% to 4% of uveitis cases. It usually begins in young and middle-aged adults, appears somewhat more often in women and is rare in children. Certain inherited versions of immune-system genes, especially one called HLA-DR4, are linked to higher risk, but most people who carry them never develop VKH. Rarely, a similar pattern of eye inflammation has followed cancer treatment with immune checkpoint inhibitors, medicines that unleash the immune system against tumors.
There is no single blood test for VKH. An eye specialist, usually a uveitis or retina specialist, makes the diagnosis by finding a characteristic pattern of inflammation in both eyes, together with the body-wide signs that point to VKH, and by ruling out other causes. A history of eye injury or eye surgery before the inflammation matters, because a similar condition called sympathetic ophthalmia can follow injury to one eye. Imaging of the back of the eye helps confirm the diagnosis and track treatment. Optical coherence tomography (OCT), a quick scan using light, shows fluid under the retina and a thickened choroid. Fluorescein angiography, in which a dye is injected into an arm vein and photographed as it passes through the eye, shows pinpoint leaks typical of VKH. Ultrasound of the eye can also show choroidal thickening. In some cases a lumbar puncture (spinal tap) finds extra white blood cells in the fluid around the brain and spinal cord, a sign of meningeal inflammation, and a hearing test may document inner-ear involvement. Because infections, other inflammatory diseases and some cancers can look similar, blood tests and other evaluation are often done before strong immune-suppressing treatment begins.
Treatment aims to stop the inflammation quickly and keep it from coming back. Early, strong treatment is linked to better vision and fewer complications, while delayed treatment and repeated flare-ups are linked to worse long-term vision. The first step is usually high-dose corticosteroids, anti-inflammatory medicines such as prednisone, sometimes started as intravenous methylprednisolone for a few days before switching to pills. The dose is then reduced very slowly, typically over at least six months. Tapering too fast is a common reason for relapse; in one study, about 59% of people treated for less than six months had a recurrence, compared with about 11% of those treated longer. Steroid eye drops and dilating drops are often added to calm inflammation at the front of the eye and ease pain. Because months of high-dose steroids can cause high blood sugar, bone thinning, stomach ulcers, cataracts and, less often, serious mood or thinking changes, many specialists add a steroid-sparing immunosuppressant early. Options include mycophenolate mofetil, azathioprine, methotrexate and cyclosporine. These medicines need regular blood tests to check for side effects and raise the risk of infection. Some, including methotrexate and mycophenolate, can cause serious birth defects, so tell your doctor if you could become pregnant or are planning a family. For inflammation that keeps returning, a biologic such as adalimumab (Humira), an injected medicine that blocks an inflammatory signal called tumor necrosis factor, may be used; it is approved for several forms of non-infectious uveitis, including the kind VKH causes, and it requires screening for tuberculosis and attention to infections. Complications such as cataract and glaucoma are treated as they arise, with the usual options for those conditions.
VKH often follows a recognizable course. The flu-like start lasts a few days, then blurred vision develops, usually in both eyes within about two weeks. With treatment, the fluid under the retina typically clears over weeks and vision often improves substantially. Over the following months the back of the eye may lose pigment, giving it an orange-red appearance doctors call a sunset glow fundus, and skin or hair color changes may appear. The long treatment course is a real part of daily life: months of steroids, regular eye visits and, for many people, immunosuppressant medicines with routine blood monitoring. Some people stay in remission after treatment ends, while others have repeated flare-ups, most often inflammation at the front of the eye. Recurrent inflammation is when vision-threatening complications such as cataract, glaucoma and scarring under the retina tend to develop, and about half of affected eyes develop at least one complication over time. For that reason, follow-up with an eye specialist continues even when vision feels normal, including eye pressure checks. Outlook is best when treatment starts early and inflammation is fully controlled. People whose vision is better when treatment starts are more likely to end with good vision. Outcomes still vary, and older age at onset, repeated flares and onset in childhood are linked to a harder course.
See an eye doctor promptly, ideally within a day, for new blurred vision in one or both eyes, especially if it follows a flu-like illness with headache or a stiff neck, or comes with ringing in the ears or hearing loss. Early treatment makes a real difference to how much vision is preserved. A severe headache with fever and a stiff neck needs emergency care right away, because infections such as meningitis must be ruled out, especially if you take steroids or immunosuppressants. If you are already being treated, contact your eye care team right away if vision blurs again or you develop eye pain, redness or light sensitivity, which can signal a flare, particularly while steroids are being reduced. While taking steroids or immunosuppressants, call your care team about fever or other signs of infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Vogt-Koyanagi-Harada Syndrome is like, what's helped you, or ask the community a question.